Here we describe, for the first time, a hemodialysis patient suffering from adult T-cell leukemia/lymphoma (ATL) who was treated with mogamulizumab, a defucosylated anti-CC chemokine receptor 4 (CCR4) monoclonal antibody [1] .
just before the second infusion (Ctrough) were 14,104.8 ng/mL, 16,092.2 ng/mL, and 5901.2 ng/mL, respectively. The plasma levels of mogamulizumab before and after hemodialysis were comparable, and Ctrough was in the range of published data [2] , suggesting that therapeutic levels of mogamulizumab may be maintained in patients undergoing dialysis ( Figure 1 ). Five months after the mogamulizumab treatment the leukemia relapsed. However, the patient did not accept any further treatment or a rechallenge with mogamulizumab. She was managed with best supportive care, and she died 10 months after diagnosis with ATL.
ATL is an aggressive peripheral T-cell neoplasm that cannot usually be cured by conventional chemotherapy [4, 5] . Allogeneic hematopoietic stem cell transplantation is now considered the only curable treatment for young patients with ATL, but it is not applied to elderly patients because of higher toxicities. Currently, chemotherapy is the only therapeutic option for elderly ATL patients but there are concers about their safety and efficacy [6] . Mogamulizumab is a humanized anti-CCR4 antibody with a defucosylated Fc region and has been used to treat relapsed/refractory CCR4-positive ATL with 50% efficacy in a phase II study [3, 7] . The fucose content in the oligosaccharide structure in the Fc region of mogamulizumab is reduced using Potelligent technology, which enhances the antibody-dependent cellular toxicity because of increased binding affinity to the Fcγ receptor on effector cells [8] . More recently, mogamulizumab was also approved for the treatment of relapsed CCR4-positive peripheral T-cell lymphoma and cutaneous T-cell lymphoma in Japan [9] .
To date, limited data exist about the application of mogamulizumab in patients undergoing hemodialysis. Here, mogamulizumab treatment resulted in complete remission of an elderly ATL patient with no major adverse events such as infusion reaction or skin rash (including re-exacerbation of renal function). Thus, administration of mogamulizumab may be considered as a safe therapeutic option in this setting. The present case shows that therapeutic mogamulizumab levels can be achieved and maintained in patients undergoing hemodialysis as mogamulizumab is not eliminated by the procedure.
